Just to be clear, this was a propensity matching study, in which real edaravone pts were matched against patients in the same claims database who didn't get the drug, using variables like age and gender to get some similarity. It was not a prospective trial where a patient shows up for the trial and is randomized to one arm or the other, which would be the gold standard.
Propensity scores are subject to a lot of noise , and esp. in ALS, traditional variables that are used for matching don't tell the whole story.